EVI1 as a Marker for Lymph Node Metastasis in HNSCC.

Area of Science:

• Oncology
• Cancer Biology
• Molecular Pathology

Background:

• Head and neck squamous cell carcinoma (HNSCC) has a poor prognosis with limited reliable prognostic markers beyond p16 expression.
• Current treatments often lead to significant quality of life impairment.
• Ecotropic Viral Integration Site 1 (EVI1) is a known prognostic marker in other cancers, but its role in HNSCC is unclear.

Purpose of the Study:

• To investigate the prognostic relevance of Ecotropic Viral Integration Site 1 (EVI1) expression in Head and Neck Squamous Cell Carcinoma (HNSCC).
• To determine if EVI1 expression correlates with clinical characteristics, particularly lymph node metastasis, in HNSCC.

Main Methods:

• Analysis of EVI1 expression using immunohistochemistry in a cohort of 389 primary HNSCC tissue samples.
• Correlation of EVI1 expression levels with patient clinical characteristics, including lymph node metastasis status.

Main Results:

• EVI1 expression in primary HNSCC tumors did not correlate with patient survival.
• A high expression of EVI1 in primary tumors was significantly associated with the presence of lymph node metastases.

Conclusions:

• EVI1 expression may not be a prognostic marker for overall survival in HNSCC.
• EVI1 could serve as a valuable biomarker for predicting occult lymph node metastasis in clinically node-negative (cN0) HNSCC patients.
• Identifying EVI1 as a potential biomarker could aid in risk stratification and treatment decisions for HNSCC.